P2X4 Antagonist Composition for Inflammatory Respiratory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), lack a radical cure and are associated with significant side effects, and existing P2X4 receptor antagonists have unclear efficacy for these conditions.
Innovation Solution
A pharmaceutical composition containing compounds with P2X4 receptor antagonistic action, represented by General Formulas (A) to (BII), is developed for preventing or treating inflammatory respiratory diseases, including COPD and other conditions like bronchial asthma and interstitial lung diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bronchodilators or inhaled steroids are administered to treat COPD, then respiratory symptoms are relieved, but side effects occur (tachycardia, tremor, hypokalemia, dysphonia)
Solution Approach 1:
The patent changes the pharmacological target from traditional bronchodilators and steroids to P2X4 receptor antagonists, representing a fundamental parameter change in the mechanism of action. This new target class provides therapeutic efficacy while avoiding the specific side effects associated with conventional treatments.
Solution Approach 2:
The patent extracts the beneficial therapeutic effect from the class of P2X4 receptor antagonists while leaving behind the harmful side effects associated with bronchodilators and steroids. By targeting a different receptor system, the invention separates the desired therapeutic outcome from the adverse effects.
2Reliability
If P2X4 receptor antagonists are used, then cough reflex is suppressed, but efficacy for inflammatory respiratory disease is unclear
Solution Approach 1:
The patent demonstrates that P2X4 receptor antagonists have multiple functions: they suppress cough reflex and also treat inflammatory respiratory diseases. The invention reveals the universal applicability of this receptor target across different respiratory conditions, transforming it from a single-function cough suppressant to a multi-functional therapeutic agent.
Solution Approach 2:
The patent provides experimental evidence and clinical data that feedback confirms the therapeutic efficacy of P2X4 receptor antagonists in inflammatory respiratory diseases. This feedback loop validates the unknown therapeutic effect and establishes the compound class as effective for the intended indication.
3Duration of action of stationary object
If conventional treatments are used for COPD, then disease progression is managed, but radical cure is not achieved
Solution Approach 1:
The patent changes the therapeutic approach from symptomatic management to potential curative treatment by targeting P2X4 receptors, which are involved in inflammatory pathways. This parameter change in mechanism of action aims to address the underlying disease process rather than just managing symptoms, potentially achieving radical cure.
Solution Approach 2:
The patent applies P2X4 receptor antagonists early in the disease course to prevent irreversible lung damage before it occurs. By acting preliminarily to block inflammatory pathways, the treatment aims to prevent disease progression and potentially reverse early changes, achieving curative effects rather than just long-term management.
Data Source
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating respiratory disease, particularly, inflammatory respiratory disease, the pharmaceutical composition including a compound having a P2X4 receptor antagonistic action or a pharmaceutically acceptable salt of the compound as an active ingredient.